FlowBank
en
LiveWire

1045 days ago • Posted by William Ramstein

Biogen drug approval boosts biotech index after underperforming in March

Biogen's new Alzheimer disease treatment drug approval sent the biotech index on an up ramp that drove the Nasdaq Biotech index to a point not seen in the past seven months. This FDA approval is a first for an Alzheimer's Drug in nearly two decades. Shares of Eli Lilly & Co. jumped 10% and closed at a record high, while Biogen’s partner in Japan, Eisai Co., surged 56% in U.S. trading, the biggest gain ever for the stock. Small-cap companies working on treatments for the disease also climbed: Cassava Sciences Inc. rose 5.4%, while Annovis Bio Inc. gained 7.4%.

Source: Bloomberg

#Technology
bg_newsletter

 

CFDs are complex instruments and are not suitable for everyone as they can rapidly trigger losses that exceed your deposits. You should consider whether you understand how CFDs work. Please see our Risk Disclosure Notice so you can fully understand the risks involved and whether you can afford to take the risk.


This website is owned and operated by FlowBank S.A, a company regulated by the Swiss Financial Market Supervisory Authority (FINMA) and a member of esisuisse. The list of banks and securities firms authorized by FINMA can be accessed here. Depositor protection in Switzerland is provided by esissuisse for a maximum of CHF 100,000.- per client. Details concerning this protection system are explained at www.esisuisse.ch/en

FlowBank is affiliated with the Swiss Banking Ombudsman. Therefore, if you wish to initiate a mediation procedure with the Swiss Banking Ombudsman after your complaint to FlowBank, please contact the Ombudsman according to the instructions provided on its website: https://bankingombudsman.ch/en/

 

The information on this site is not directed at residents of the United States, Belgium, Canada, or any person in any country or jurisdiction where such distribution or use would be contrary to local laws or regulations.

 

Trading Forex and other leveraged products carries high risks and may not be apt for everyone. Before you consider trading these instruments please assess your experience, goals, and financial situation. You could lose your initial investment, so don't use funds you can't afford to lose or that are essential for personal or family needs. You can consult a licensed financial advisor and ensure you have the risk tolerance and experience.


Apple, iPad, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.

FlowBank S.A, Esplanade de Pont-Rouge 9, 1211 Geneva 26, Switzerland
FlowBank S.A, Seidengasse 20, 8001 Zurich, Switzerland